Apellis Pharmaceuticals (APLS) Short Interest Ratio & Short Volume $29.93 +0.20 (+0.67%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Apellis Pharmaceuticals Short Interest DataApellis Pharmaceuticals (APLS) has a short interest of 21.48 million shares. This marks a 7.35% increase in short interest from the previous month. The short interest ratio (days to cover) is 6.9, indicating that it would take 6.9 days of the average trading volume of 2.05 million shares to cover all short positions.Current Short Interest21,480,000 sharesPrevious Short Interest20,010,000 sharesChange Vs. Previous Month+7.35%Dollar Volume Sold Short$685.43 millionShort Interest Ratio6.9 Days to CoverLast Record DateDecember 31, 2024Outstanding Shares124,390,000 sharesPercentage of Shares Shorted17.27%Today's Trading Volume1,510,921 sharesAverage Trading Volume2,047,200 sharesToday's Volume Vs. Average74% Short Selling Apellis Pharmaceuticals? Sign up to receive the latest short interest report for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAPLS Short Interest Over TimeAPLS Days to Cover Over TimeAPLS Percentage of Float Shorted Over Time Apellis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/202421,480,000 shares $685.43 million +7.4%N/A6.9 $31.91 12/15/202420,010,000 shares $664.13 million -8.3%N/A6 $33.19 11/30/202421,810,000 shares $740.01 million -5.9%N/A6.7 $33.93 11/15/202423,180,000 shares $608.94 million +11.5%N/A7.7 $26.27 10/31/202420,790,000 shares $566.74 million -1.4%N/A8.7 $27.26 10/15/202421,090,000 shares $589.47 million +38.2%N/A9.9 $27.95 9/30/202415,260,000 shares $440.10 million -0.1%N/A7.9 $28.84 9/15/202415,280,000 shares $574.83 million -5.5%N/A9.6 $37.62 8/31/202416,170,000 shares $629.01 million -0.6%N/A11.2 $38.90 8/15/202416,270,000 shares $612.08 million +2.2%N/A11.2 $37.62 Get the Latest News and Ratings for APLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/31/202415,920,000 shares $630.43 million +4.9%N/A10.6 $39.60 7/15/202415,170,000 shares $606.80 million +2.4%N/A10.3 $40.00 6/30/202414,810,000 shares $568.11 million +6.6%N/A10.1 $38.36 6/15/202413,900,000 shares $583.80 million +6.0%N/A10.1 $42.00 5/31/202413,120,000 shares $514.96 million +4.2%N/A9.6 $39.25 5/15/202412,590,000 shares $527.77 million +1.6%N/A8.6 $41.92 4/30/202412,390,000 shares $547.51 million +16.1%N/A8.4 $44.19 4/15/202410,670,000 shares $549.51 million +2.2%N/A8 $51.50 3/31/202410,440,000 shares $613.66 million -1.4%N/A7.1 $58.78 3/15/202410,590,000 shares $600.88 million +5.3%N/A6.7 $56.74 2/29/202410,060,000 shares $623.42 million -2.0%N/A5.1 $61.97 2/15/202410,270,000 shares $694.05 million -3.8%N/A4.9 $67.58 1/31/202410,670,000 shares $675.30 million -11.3%N/A5.1 $63.29 1/15/202412,030,000 shares $844.87 million +2.9%N/A5.4 $70.23 12/31/202311,690,000 shares $699.76 million -9.9%N/A5.1 $59.86 12/15/202312,980,000 shares $683.79 million -14.9%N/A5.2 $52.68 11/30/202315,260,000 shares $822.06 million -5.5%N/A6.4 $53.87 11/15/202316,140,000 shares $781.18 million -0.6%N/A6.9 $48.40 10/31/202316,230,000 shares $789.75 million -12.7%N/A5.2 $48.66 10/15/202318,590,000 shares $900.50 million +10.9%N/A4.5 $48.44 9/30/202316,770,000 shares $637.93 million +23.2%N/A3.3 $38.04 9/15/202313,610,000 shares $604.83 million +10.6%N/A2.9 $44.44 8/31/202312,310,000 shares $519.61 million -10.5%N/A2.7 $42.21 8/15/202313,750,000 shares $449.90 million +43.2%N/A3.1 $32.72 7/31/20239,600,000 shares $247.20 million +1.3%N/A2.6 $25.75 7/15/20239,480,000 shares $801.06 million -1.2%N/A3.5 $84.50 6/30/20239,590,000 shares $873.65 million -16.3%N/A6 $91.10 6/15/202311,460,000 shares $1.03 billion +0.9%N/A6.7 $89.60 5/31/202311,360,000 shares $975.26 million +3.3%N/A7 $85.85 5/15/202311,000,000 shares $969.21 million +7.0%N/A5.6 $88.11This coin could surge during Trump’s first week in office. (Ad)Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one virtually unknown coin could thrive in the first year of Trump's crypto bull market …starting during his first week in office.Click here to find out more about this coin. 4/30/202310,280,000 shares $857.66 million -16.6%N/A5.4 $83.43 4/15/202312,330,000 shares $998.11 million +0.4%N/A6.7 $80.95 3/31/202312,280,000 shares $809.99 million +1.1%N/A7.1 $65.96 3/15/202312,150,000 shares $796.19 million +13.1%N/A7.6 $65.53 2/28/202310,740,000 shares $703.26 million +18.5%N/A7.4 $65.48 2/15/20239,060,000 shares $479.82 million -0.6%N/A6.5 $52.96 1/31/20239,110,000 shares $480.37 million -5.0%N/A6.9 $52.73 1/15/20239,590,000 shares $504.05 million +4.6%N/A7.4 $52.56 12/30/20229,170,000 shares $474.18 million -8.8%N/A7.1 $51.71 12/15/202210,050,000 shares $526.72 million +1.9%N/A6.9 $52.41 11/30/20229,860,000 shares $492.31 million -5.1%N/A6.6 $49.93 11/15/202210,390,000 shares $484.28 million +6.8%N/A6.3 $46.61 10/31/20229,730,000 shares $588.57 million +10.8%N/A6.6 $60.49 10/15/20228,780,000 shares $499.93 million -10.6%N/A6.4 $56.94 9/30/20229,820,000 shares $670.71 million +7.9%N/A6.8 $68.30 9/15/20229,100,000 shares $589.23 million +8.6%N/A6.9 $64.75 8/31/20228,380,000 shares $507.07 million +4.9%N/A6.5 $60.51 8/15/20227,990,000 shares $548.43 million -18.8%N/A7.4 $68.64 7/31/20229,840,000 shares $553.80 million +5.0%N/A8.8 $56.28 7/15/20229,370,000 shares $431.68 million -4.4%N/A8.8 $46.07 6/30/20229,800,000 shares $443.16 million +7.1%N/A9.9 $45.22 6/15/20229,150,000 shares $376.71 million +2.0%N/A8.1 $41.17 5/31/20228,970,000 shares $371.81 million -2.0%N/A7.5 $41.45 5/15/20229,150,000 shares $360.97 million +3.7%N/A7.5 $39.45 4/30/20228,820,000 shares $383.93 million +12.4%N/A7.7 $43.53 4/15/20227,850,000 shares $414.56 million +7.7%N/A6.8 $52.81 3/31/20227,290,000 shares $370.40 million +14.1%N/A6.3 $50.81 3/15/20226,390,000 shares $255.92 million -7.0%8.0%6.8 $40.05 2/28/20226,870,000 shares $292.18 million -1.3%8.5%8.1 $42.53 2/15/20226,960,000 shares $327.61 million -4.7%8.8%8.2 $47.07 1/31/20227,300,000 shares $293.97 million +17.0%9.3%6.8 $40.27 1/15/20226,240,000 shares $251.85 million -6.7%7.9%5.9 $40.36 12/31/20216,690,000 shares $316.30 million -7.3%8.5%6.5 $47.28 12/15/20217,220,000 shares $320.06 million +9.1%9.2%6.3 $44.33 11/30/20216,620,000 shares $278.57 million +12.4%8.6%3.7 $42.08 11/15/20215,890,000 shares $247.85 million -1.0%7.6%3.2 $42.08 10/29/20215,950,000 shares $182.90 million +4.0%8.6%3.6 $30.74 10/15/20215,720,000 shares $198.08 million -10.2%8.3%3.6 $34.63 9/30/20216,370,000 shares $209.96 million +11.4%9.2%4 $32.96 9/15/20215,720,000 shares $194.02 million +10.6%8.3%3.7 $33.92 8/31/20215,170,000 shares $340.44 million +2.4%7.6%5.8 $65.85 8/13/20215,050,000 shares $290.17 million +2.9%7.5%6.4 $57.46 7/30/20214,910,000 shares $314.19 million -21.2%7.9%5.6 $63.99 7/15/20216,230,000 shares $390.18 million +4.9%10.0%7.1 $62.63 6/30/20215,940,000 shares $375.41 million -0.5%9.5%7 $63.20 6/15/20215,970,000 shares $362.08 million +6.4%9.6%7.7 $60.65 5/28/20215,610,000 shares $315.73 million -18.7%9.0%7.2 $56.28 5/14/20216,900,000 shares $314.92 million -10.6%11.0%8.9 $45.64 4/30/20217,720,000 shares $372.41 million -4.0%N/A12.1 $48.24 4/15/20218,040,000 shares $357.62 million +4.6%N/A12.4 $44.48This coin could surge during Trump’s first week in office. (Ad)Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one virtually unknown coin could thrive in the first year of Trump's crypto bull market …starting during his first week in office.Click here to find out more about this coin. 3/31/20217,690,000 shares $323.36 million +9.2%N/A11.7 $42.05 3/15/20217,040,000 shares $328.49 million -13.2%N/A10.7 $46.66 2/26/20218,110,000 shares $365.36 million +4.7%12.8%11.8 $45.05 2/12/20217,750,000 shares $366.73 million +1.2%12.4%11 $47.32 1/29/20217,660,000 shares $343.93 million -14.3%12.4%10.6 $44.90 1/15/20218,940,000 shares $479.18 million -1.1%15.1%12.5 $53.60 12/31/20209,040,000 shares $516.46 million +7.1%15.3%13.4 $57.13 12/15/20208,440,000 shares $439.30 million -6.6%14.3%12.3 $52.05 11/30/20209,040,000 shares $426.87 million -9.1%15.3%14.6 $47.22 11/15/20209,940,000 shares $384.98 million -2.5%16.8%16.7 $38.73 10/30/202010,190,000 shares $331.79 million -4.2%17.2%18.1 $32.56 10/15/202010,640,000 shares $376.87 million -2.4%18.0%18.6 $35.42 9/30/202010,900,000 shares $328.85 million +3.8%18.5%16.8 $30.17 9/15/202010,500,000 shares $327.60 million +1.9%17.8%15.5 $31.20 8/31/202010,300,000 shares $317.55 million +0.9%17.5%14 $30.83 8/14/202010,210,000 shares $289.76 million +0.7%17.3%13 $28.38 7/31/202010,140,000 shares $262.52 million +0.8%17.2%12 $25.89 7/15/202010,060,000 shares $321.01 million +4.4%17.1%10.9 $31.91 6/30/20209,640,000 shares $314.84 million +10.2%16.4%10.1 $32.66 6/15/20208,750,000 shares $285.16 million +7.2%14.9%9.1 $32.59 5/29/20208,160,000 shares $277.93 million +11.6%13.9%7.8 $34.06 5/15/20207,310,000 shares $226.61 million +20.2%12.4%6.9 $31.00 4/30/20206,080,000 shares $208.36 million +7.8%10.5%5.9 $34.27 4/15/20205,640,000 shares $180.37 million -1.2%9.7%5.9 $31.98 3/31/20205,710,000 shares $210.53 million -2.0%9.9%3.8 $36.87 3/13/20205,825,200 shares $163.98 million -9.6%18.3%5.6 $28.15 2/28/20206,440,000 shares $153.92 million +4.0%20.3%4.5 $23.90 2/14/20206,190,000 shares $191.58 million -7.2%11.1%4.3 $30.95 1/31/20206,670,000 shares $229.71 million No Change12.6%4.7 $34.44 APLS Short Interest - Frequently Asked Questions What is Apellis Pharmaceuticals' current short interest? Short interest is the volume of Apellis Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of December 31st, traders have sold 21,480,000 shares of APLS short. Learn More on Apellis Pharmaceuticals' current short interest. What is a good short interest ratio for Apellis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APLS shares currently have a short interest ratio of 7.0. Learn More on Apellis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Apellis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apellis Pharmaceuticals: SG Americas Securities LLC, Jane Street Group LLC, Wolverine Trading LLC, Ikarian Capital LLC, Walleye Trading LLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Apellis Pharmaceuticals' short interest increasing or decreasing? Apellis Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 21,480,000 shares, an increase of 7.3% from the previous total of 20,010,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Apellis Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Apellis Pharmaceuticals: Viatris Inc. (2.96%), Intra-Cellular Therapies, Inc. (1.87%), Summit Therapeutics Inc. (2.70%), Moderna, Inc. (11.03%), Dr. Reddy's Laboratories Limited (1.57%), Catalent, Inc. (8.12%), Sarepta Therapeutics, Inc. (5.37%), Qiagen (1.38%), Vaxcyte, Inc. (11.49%), Ascendis Pharma A/S (5.64%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short Apellis Pharmaceuticals stock? Short selling APLS is an investing strategy that aims to generate trading profit from Apellis Pharmaceuticals as its price is falling. APLS shares are trading up $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Apellis Pharmaceuticals? A short squeeze for Apellis Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of APLS, which in turn drives the price of the stock up even further. How often is Apellis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLS, twice per month. The most recent reporting period available is December, 31 2024. More Short Interest Resources from MarketBeat Related Companies VTRS Short Interest Data ITCI Short Interest Data SMMT Short Interest Data MRNA Short Interest Data RDY Short Interest Data CTLT Short Interest Data SRPT Short Interest Data QGEN Short Interest Data PCVX Short Interest Data ASND Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:APLS) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.